CheckMate 77T

Prespecified interim analysis results from CheckMate 77T trial of neoadjuvant nivolumab or placebo plus chemotherapy and adjuvant nivolumab or placebo in stage II to IIIB NSCLC, as presented at ESMO Congress 2023 and reported by Clinical Care Options (CCO)

Cancers, Free Full-Text

IJMS, Free Full-Text

Stephen V Liu, MD on X: #ESMO23 Dr. Tina Cascone presents the

CheckMate-77T Trial Meets Primary EFS End Point in Resectable NSCLC

Adding Adjuvant Nivolumab Builds on Standard of Care for

Dr. Antonio Calles 🫁🚭 on X: CHECKMATE-77T: Neoadjuvant chemo

Bristol Myers Squibb Announces Perioperative Regimen of

JCM, Free Full-Text

Ashwin Mohandas - DM Medical & Haemato-Oncology - Regional Cancer